Title:
USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE
Document Type and Number:
WIPO Patent Application WO/2014/148053
Kind Code:
A1
Abstract:
This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of cartilage disease. This invention also relates to a pharmaceutical composition for the treatment of cartilage disease which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of cartilage disease in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.
Inventors:
OKUMURA TAKAKO (JP)
Application Number:
PCT/JP2014/001597
Publication Date:
September 25, 2014
Filing Date:
March 19, 2014
Export Citation:
Assignee:
ASKAT INC (JP)
International Classes:
A61K45/00; A61K31/341; A61K31/381; A61K31/437; A61K31/44; A61P19/02; C07D213/89; C07D307/64; C07D333/38; C07D471/04
Domestic Patent References:
| WO2002032900A2 | 2002-04-25 | |||
| WO2005021508A1 | 2005-03-10 | |||
| WO2005105732A1 | 2005-11-10 | |||
| WO2004067524A1 | 2004-08-12 | |||
| WO2008017164A1 | 2008-02-14 | |||
| WO2006095268A1 | 2006-09-14 | |||
| WO2002032900A2 | 2002-04-25 | |||
| WO2005021508A1 | 2005-03-10 | |||
| WO2005105732A1 | 2005-11-10 | |||
| WO2004067524A1 | 2004-08-12 | |||
| WO2008017164A1 | 2008-02-14 |
Other References:
ATTUR, M. ET AL.: "Prostaglandin E2 Exerts Catabolic Effects in Osteoarthritis Cartilage: Evidence for Signaling via the EP 4 Receptor", JOURNAL OF IMMUNOLOGY, vol. 181, no. 7, 1 October 2008 (2008-10-01), pages 5082 - 5088, XP055285665, DOI: 10.4049/JIMMUNOL.181.7.5082
LI, X. ET AL.: "Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the thophysiology of osteoarthritis", ARTHRITIS & RHEUMATISM, vol. 60, no. 2, 1 February 2009 (2009-02-01), pages 513 - 523, XP055285673, DOI: 10.1002/ART.24258
BLOUIN, M. ET AL.: "The Discovery of 4-{1-[({2,5-Dimethyl-4- [4-(trifluoromethyl)benzyl]- 3-thienyl}carbonyl)amino]cyclo propyl}benzoic Acid ( MK -2894), A Potent and Selective Prostaglandin E2 Subtype 4 Receptor Antagonist", J.MED.CHEM, vol. 53, no. 5, 1 January 2010 (2010-01-01), pages 2227 - 2238, XP055077161, DOI: 10.1021/JM901771H
AKIO MURASE ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 580, no. 1-2, 1 February 2008 (2008-02-01), pages 116 - 121
OKUMURA T. ET AL., JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 60, no. 6, 1 June 2008 (2008-06-01), pages 723 - 730
BIOCHIM BIOPHYS ACTA, vol. 1259, 1995, pages 109 - 19
MARC BLOUIM ET AL., J. MED. CHEM.
"Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
AGRAWAL ET AL., METHODS IN MOLECULAR BIOLOGY: PROTOCOLS FOR OLIGONUCLEOTIDES AND ANALOGS, vol. 20, 1993
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
EUR J PHARMACOL., vol. 340, 1997, pages 227 - 241
RHEUMATOL INT., vol. 33, no. 2, February 2013 (2013-02-01), pages 401 - 11
See also references of EP 2976105A4
LI, X. ET AL.: "Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the thophysiology of osteoarthritis", ARTHRITIS & RHEUMATISM, vol. 60, no. 2, 1 February 2009 (2009-02-01), pages 513 - 523, XP055285673, DOI: 10.1002/ART.24258
BLOUIN, M. ET AL.: "The Discovery of 4-{1-[({2,5-Dimethyl-4- [4-(trifluoromethyl)benzyl]- 3-thienyl}carbonyl)amino]cyclo propyl}benzoic Acid ( MK -2894), A Potent and Selective Prostaglandin E2 Subtype 4 Receptor Antagonist", J.MED.CHEM, vol. 53, no. 5, 1 January 2010 (2010-01-01), pages 2227 - 2238, XP055077161, DOI: 10.1021/JM901771H
AKIO MURASE ET AL., EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 580, no. 1-2, 1 February 2008 (2008-02-01), pages 116 - 121
OKUMURA T. ET AL., JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 60, no. 6, 1 June 2008 (2008-06-01), pages 723 - 730
BIOCHIM BIOPHYS ACTA, vol. 1259, 1995, pages 109 - 19
MARC BLOUIM ET AL., J. MED. CHEM.
"Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
AGRAWAL ET AL., METHODS IN MOLECULAR BIOLOGY: PROTOCOLS FOR OLIGONUCLEOTIDES AND ANALOGS, vol. 20, 1993
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
EUR J PHARMACOL., vol. 340, 1997, pages 227 - 241
RHEUMATOL INT., vol. 33, no. 2, February 2013 (2013-02-01), pages 401 - 11
See also references of EP 2976105A4
Attorney, Agent or Firm:
IWATANI, Ryo (1-31 Dojima 2-chome, Kita-ku, Osaka-sh, Osaka 03, JP)
Download PDF:
Previous Patent: SYRINGE PUMP AND SYRINGE PUMP CONTROL METHOD
Next Patent: ELECTRICITY-STORAGE SYSTEM, MONITORING DEVICE, AND POWER CONTROL SYSTEM
Next Patent: ELECTRICITY-STORAGE SYSTEM, MONITORING DEVICE, AND POWER CONTROL SYSTEM